Patients with certain immune‐mediated inflammatory diseases, such as rheumatoid arthritis
(RA) and inflammatory bowel disease (IBD), have an increased risk of severe infectious …

Background & Aims Inhibitors of Janus kinases (JAKs) are being developed for treatment of
inflammatory bowel diseases and other immune-mediated diseases. Tofacitinib is effective …

ABSTRACT Introduction Janus Kinase inhibitors (JAKi) are a new class of oral therapies for
the treatment of moderate-severe ulcerative colitis with additional potential for the treatment …

Background Janus kinase (JAK) inhibitors represent a novel therapeutic class for treatment
of inflammatory bowel disease. Aims To determine the efficacy and safety of JAK inhibitors …

Objective: Janus kinase (JAK) inhibitors are a novel class of drugs that have shown efficacy
in treating immune-mediated inflammatory diseases (IMIDs). However, their safety profile in …

Janus kinase (JAK) inhibitors have heralded a paradigm shift in the management of immune-
mediated diseases. While their efficacy is well-established, the safety concerns associated …

Crohn disease (CD) and ulcerative colitis (UC) are considered chronic disorders of the
gastrointestinal tract, lifelong medication often being necessary. Furthermore, they have …

Crohn's disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated diseases of
the gastrointestinal (GI) tract. Their etiology is complex and involves immune (eg, cytokines) …

Inflammatory bowel disease (IBD) comprises ulcerative colitis (UC) and Crohn's disease
(CD), two conditions with different pathophysiology, organ involvement and manifestations …

For a significant proportion of patients with inflammatory bowel disease (IBD), primary non-
response and secondary loss of response to treatment remain significant issues. Anti-tumor …